Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2010 (2010), Article ID 473453, 11 pages
http://dx.doi.org/10.1155/2010/473453
Research Article

Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)

1Section of Hematology and Oncology, Department of Medicine, College of Medicine Research Building, University of Illinois at Chicago, 909 South Wolcott Avenue, Chicago, IL 60612, USA
2Department of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL 60612, USA
3Proteomics Core Research Facility, Rush University Medical Center, Chicago, IL 60612, USA

Received 1 July 2010; Revised 7 December 2010; Accepted 14 December 2010

Academic Editor: Bartholomew Akanmori

Copyright © 2010 Supriya Perambakam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA-Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Pronzato and M. Rondini, “Hormonotherapy of advanced prostate cancer,” Annals of Oncology, vol. 16, no. 4, pp. iv80–iv84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Kantoff, C. S. Higano, E. R. Berger et al., “Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPC),” in Proceedings of the Genitourinary Cancers Symposium of the American Society of Clinical Oncology, 2010, Abstract #8.
  4. B. H. Xue, Y. Zhang, J. A. Sosman, and D. J. Peace, “Induction of human cytotoxic T lymphocytes specific for prostate- specific antigen,” Prostate, vol. 30, no. 2, pp. 73–78, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Perambakam, B. H. Xue, J. A. Sosman, and D. J. Peace, “Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer,” Cancer Immunology, Immunotherapy, vol. 51, no. 5, pp. 263–270, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Perambakam, S. Hallmeyer, S. Reddy et al., “Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide,” Cancer Immunology, Immunotherapy, vol. 55, no. 9, pp. 1033–1042, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Lau, F. Wang, G. Jeffery et al., “Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma,” Journal of Immunotherapy, vol. 24, no. 1, pp. 66–78, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. R. A. Irizarry, B. M. Bolstad, F. Collin, L. M. Cope, B. Hobbs, and T. P. Speed, “Summaries of Affymetrix GeneChip probe level data,” Nucleic acids research, vol. 31, no. 4, p. e15, 2003. View at Google Scholar · View at Scopus
  9. N. Meidenbauer, D. T. Harris, L. E. Spitler, and T. L. Whiteside, “Generation of PSA-reactive effector cells after vaccination with a PSA- based vaccine in patients with prostate cancer,” Prostate, vol. 43, no. 2, pp. 88–100, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. C. S. Higano, P. F. Schellhammer, E. J. Small et al., “Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer,” Cancer, vol. 115, no. 16, pp. 3670–3679, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. P. W. Kantoff, T. J. Schuetz, B. A. Blumenstein et al., “Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1099–1105, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. K. Thomas-Kaskel, R. Zeiser, R. Jochim et al., “Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival,” International Journal of Cancer, vol. 119, no. 10, pp. 2428–2434, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. L. Gulley, P. M. Arlen, R. A. Madan et al., “Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer,” Cancer Immunology, Immunotherapy, vol. 59, no. 5, pp. 663–674, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. K. Palucka, H. Ueno, J. W. Fay, and J. Banchereau, “Taming cancer by inducing immunity via dendritic cells,” Immunological Reviews, vol. 220, no. 1, pp. 129–150, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. L. Disis, H. Bernhard, F. M. Shiota et al., “Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines,” Blood, vol. 88, no. 1, pp. 202–210, 1996. View at Google Scholar · View at Scopus
  16. M. L. Disis, T. A. Gooley, K. Rinn et al., “Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines,” Journal of Clinical Oncology, vol. 20, no. 11, pp. 2624–2632, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. F. O. Nestle, S. Alijagic, M. Gilliet et al., “Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells,” Nature Medicine, vol. 4, no. 3, pp. 328–332, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Thurner, I. Haendle, C. Röder et al., “Vaccination with Mage-3A1 peptide-pulsed nature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma,” Journal of Experimental Medicine, vol. 190, no. 11, pp. 1669–1678, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Banchereau, A. K. Palucka, M. Dhodapkar et al., “Immune and clinical responses in patients with metastatic melanoma to CD34 progenitor-derived dendritic cell vaccine,” Cancer Research, vol. 61, no. 17, pp. 6451–6458, 2001. View at Google Scholar · View at Scopus
  20. J. M. Timmerman, D. K. Czerwinski, T. A. Davis et al., “Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients,” Blood, vol. 99, no. 5, pp. 1517–1526, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. G. E. Peoples, J. M. Gurney, M. T. Hueman et al., “Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients,” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7536–7545, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. I. H. Haralambieva, N. Dhiman, I. G. Ovsyannikova et al., “2-5-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine,” Human Immunology, vol. 71, no. 4, pp. 383–391, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. H. Tsai, J. A. Cook, G. V. R. Chandramouli et al., “Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation,” Cancer Research, vol. 67, no. 8, pp. 3845–3852, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. C. J. B. Maia, S. Socorro, F. Schmitt, and C. R. A. Santos, “Characterization of oligoadenylate synthetase-1 expression in rat mammary gland and prostate: effects of 17β-estradiol on the regulation of OAS1g in both tissues,” Molecular and Cellular Biochemistry, vol. 314, no. 1-2, pp. 113–121, 2008. View at Publisher · View at Google Scholar · View at Scopus